SCHEMBL18070733

SCHEMBL18070733

CCOC(=O)C(=O)c1ccc2ccccc2c1C

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 2/20 0.49
ALDH1A1 P00352 4/20 0.47
HPGD P15428 1/20 0.47
CDC25A P30304 1/20 0.46
CDC25C P30307 1/20 0.46
KMT2A Q03164 4/20 0.45
MEN1 O00255 2/20 0.45
KDM4E B2RXH2 3/20 0.45
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
TSHR P16473 1/20 0.43
NCEH1 Q6PIU2 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11342375 0.85 PRNP (0.47) CDC25BALDH1A1HPGDCDC25ACDC25C
SCHEMBL13880496 0.84 CDC25B (0.63) CDC25BALDH1A1HPGDCDC25ACDC25C
SCHEMBL697232 0.84 CDC25B (0.63) CDC25BALDH1A1HPGDCDC25ACDC25C
SCHEMBL21122869 0.83 MEN1 (0.43) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL18070734 0.82 PLK1 (0.45) CDC25BALDH1A1HPGDCDC25ACDC25C
SCHEMBL18069829 0.80 TSHR (0.45) ALDH1A1HPGDKMT2AMEN1KDM4E
SCHEMBL29291611 0.77 KMT2A (0.50) CDC25BALDH1A1HPGDCDC25ACDC25C
SCHEMBL14144960 0.77 CYP1A2 (0.47) CDC25BALDH1A1HPGDKMT2AMEN1
SCHEMBL18070708 0.77 MAPT (0.44) ALDH1A1KMT2AMEN1KDM4EMAPK1
SCHEMBL18069879 0.77 ALDH1A1 (0.49) ALDH1A1HPGDKMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759769-B2 Glucosylceramide synthase inhibitors for the treatment of diseases BIOMARIN PHARMECEUTICAL INC (US) 2020-09-01 US disclosed
US-20190248754-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMECEUTICAL INC (US) 2019-08-15 US disclosed
US-10227312-B2 Glucosylceramide synthase inhibitors for the treatment of diseases BIOMARIN PHARMACEUTICAL INC. (US) 2019-03-12 US disclosed
US-20180044302-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2018-02-15 US disclosed
US-20180044302-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2018-02-15 US disclosed
WO-2016145153-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. (US) 2016-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10759769-B2 Glucosylceramide synthase inhibitors for the treatment of diseases GBA1, UGCG, GBA2 CDC25B 3280/4885ALDH1A1 1342/4885HPGD 613/4885
US-20180044302-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES GBA1, UGCG, GBA2 CDC25B 3280/4885ALDH1A1 1342/4885HPGD 613/4885
US-20190248754-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES GBA1, UGCG, GBA2 CDC25B 3280/4885ALDH1A1 1342/4885HPGD 613/4885
US-10227312-B2 Glucosylceramide synthase inhibitors for the treatment of diseases GBA1, UGCG, GBA2 CDC25B 3280/4885ALDH1A1 1342/4885HPGD 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.